Get our Free Drug Patent Expiration Updates

Serving hundreds of leading biopharmaceutical companies globally:

Cantor Fitzgerald
Covington
Dow
Colorcon
AstraZeneca
US Army
Deloitte
Daiichi Sankyo
Healthtrust

Generated: December 13, 2018

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR VASOTEC

« Back to Dashboard

Clinical Trials for Vasotec

Trial ID Title Status Sponsor Phase Summary
NCT00248807 A Study of Blood Pressure and Blood Supply to the Brain in Persons With a Spinal Cord Injury. Completed VA Office of Research and Development N/A The purpose of this study is to determine how blood pressure and blood flow are controlled during head-up tilt in a semi-upright position. In this investigation we are studying blood pressure and blood flow to the brain, with and without a medication which lowers blood pressure (Vasotec). We will determine how persons with a spinal cord injury are able to maintain blood flow to the brain (not get dizzy) as they assume a more upright position and their blood pressure decreases.
NCT01413542 Pharmacogenetics of Ace Inhibitor-Associated Angioedema Completed Vanderbilt University N/A The investigators would like to find out if sitagliptin (dipeptidyl peptidase-4 or DPP4 inhibition), a drug to treat diabetes, affects blood vessel relaxation in healthy people receiving enalapril (angiotensin converting enzyme or ACE inhibition), a blood pressure medicine. Understanding how these drugs interact in healthy people will help us learn their potential effects in people who have diabetes.
NCT01669434 Chronic Angiotensin Converting Enzyme Inhibitors in Intermediate Risk Surgery Enrolling by invitation University of Nebraska Phase 4 Primary research hypothesis: Patients who continue their chronic ACEI therapy up to and including the morning of an intermediate risk surgery will experience more intraoperative hypotension than those who hold their chronic ACEI perioperatively. Secondary research hypothesis #1: Patients who continue their chronic ACEI up to and including the morning of an intermediate risk surgery will experience better postoperative control of hypertension than those who hold their chronic ACEI perioperatively. Secondary research hypothesis #2: Patients who continue their chronic ACEI up to and including the morning of an intermediate risk surgery will experience less acute renal failure than those who hold their chronic ACEI perioperatively. Secondary research hypothesis #3: Patients with a preoperative systolic blood pressure less than 110 mmHg who are continued on their chronicACEI therapy perioperatively will have a significant decrease in blood pressure during anesthesia compared to those who have a preoperative systolic blood pressure greater than 110 who are continued on their chronic ACEI. Secondary research hypothesis #4: Patients above the age of 64 who are continued on their chronic ACEI therapy perioperatively will have a significant decrease in blood pressure during anesthesia compared to those aged 64 or younger who are continued on their chronic ACEI.
NCT01705392 Bevacizumab vs Dacarbazine in Metastatic Melanoma Suspended Norwegian Cancer Society Phase 2 The purpose of this study is to compare efficacy of bevacizumab monotherapy with standard chemotherapy (DTIC) in patients with metastatic malignant melanoma. In addition, we want to evaluate the predictive value of a set biomarkers associated with vascular endothelial growth factor (VEGF) dependent angiogenesis. Also, we aim to identify mechanisms causing acquired resistance to treatment with bevacizumab and escape mechanisms caused by other angiogenic growth factors than VEGF. Finally, we want to analyze safety and influence on outcome variables by primary prevention of bevacizumab induced hypertension by low dose beta blockers in comparison with an ACE inhibitor.
NCT01705392 Bevacizumab vs Dacarbazine in Metastatic Melanoma Suspended The Norwegian Melanoma Group Phase 2 The purpose of this study is to compare efficacy of bevacizumab monotherapy with standard chemotherapy (DTIC) in patients with metastatic malignant melanoma. In addition, we want to evaluate the predictive value of a set biomarkers associated with vascular endothelial growth factor (VEGF) dependent angiogenesis. Also, we aim to identify mechanisms causing acquired resistance to treatment with bevacizumab and escape mechanisms caused by other angiogenic growth factors than VEGF. Finally, we want to analyze safety and influence on outcome variables by primary prevention of bevacizumab induced hypertension by low dose beta blockers in comparison with an ACE inhibitor.
NCT01705392 Bevacizumab vs Dacarbazine in Metastatic Melanoma Suspended Haukeland University Hospital Phase 2 The purpose of this study is to compare efficacy of bevacizumab monotherapy with standard chemotherapy (DTIC) in patients with metastatic malignant melanoma. In addition, we want to evaluate the predictive value of a set biomarkers associated with vascular endothelial growth factor (VEGF) dependent angiogenesis. Also, we aim to identify mechanisms causing acquired resistance to treatment with bevacizumab and escape mechanisms caused by other angiogenic growth factors than VEGF. Finally, we want to analyze safety and influence on outcome variables by primary prevention of bevacizumab induced hypertension by low dose beta blockers in comparison with an ACE inhibitor.
NCT02623036 The Use of Ambulatory Blood Pressure Monitors to Assess Angiotensin Converting Enzyme Inhibitors Recruiting Memorial Health University Medical Center Phase 1 The purpose of this study is to use ambulatory blood pressure monitors to investigate whether enalapril is superior to lisinopril in managing nocturnal hypertension in patients with resistant hypertension currently treated with daytime angiotensin converting enzyme inhibitors.
Trial ID Title Status Sponsor Phase Summary

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

Clinical Trial Conditions for Vasotec

Condition Name

Condition Name for Vasotec
Intervention Trials
Hypertension 2
Heart Failure With Reduced Ejection Fraction 1
Unresectable Malignant Melanoma 1
Diabetes Type 2 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Condition MeSH

Condition MeSH for Vasotec
Intervention Trials
Hypertension 2
Hypotension, Orthostatic 1
Melanoma 1
Hypotension 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Locations for Vasotec

Trials by Country

Trials by Country for Vasotec
Location Trials
United States 4
Norway 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Trials by US State

Trials by US State for Vasotec
Location Trials
Georgia 1
Nebraska 1
Tennessee 1
New York 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Progress for Vasotec

Clinical Trial Phase

Clinical Trial Phase for Vasotec
Clinical Trial Phase Trials
Phase 4 2
Phase 2 1
Phase 1 1
[disabled in preview] 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Status

Clinical Trial Status for Vasotec
Clinical Trial Phase Trials
Completed 2
Not yet recruiting 1
Recruiting 1
[disabled in preview] 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Sponsors for Vasotec

Sponsor Name

Sponsor Name for Vasotec
Sponsor Trials
The Norwegian Melanoma Group 1
Norwegian Cancer Society 1
University of Wisconsin, Madison 1
[disabled in preview] 4
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Sponsor Type

Sponsor Type for Vasotec
Sponsor Trials
Other 8
Industry 1
U.S. Fed 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Johnson and Johnson
Moodys
Covington
US Department of Justice
US Army
Citi
Cantor Fitzgerald
AstraZeneca
Harvard Business School

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.